Difference between revisions of "Moxetumomab pasudotox (Lumoxiti)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= Antibody-drug conjugate targeted against CD22 =Preliminary data= ==Hairy cell leukemia== # Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, St...") |
m |
||
| Line 1: | Line 1: | ||
=Mechanism of action= | =Mechanism of action= | ||
| − | + | A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) | |
=Preliminary data= | =Preliminary data= | ||
| Line 12: | Line 12: | ||
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
| − | [[Category: | + | [[Category:Immunotoxin]] |
[[Category:Anti-CD22 antibodies]] | [[Category:Anti-CD22 antibodies]] | ||
Revision as of 14:46, 14 December 2014
Mechanism of action
A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38)
Preliminary data
Hairy cell leukemia
- Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012 May 20;30(15):1822-8. Epub 2012 Feb 21. PubMed
Also known as
CAT-8015